Literature DB >> 11124688

Peripheral blood progenitor cell mobilization in three groups of subjects: a comparison of leukapheresis yield and timing.

Y C Linn1, K K Heng, S Rohimah, Y T Goh.   

Abstract

In this review, we analyse the peripheral blood progenitor cell mobilization yield of three categories of subjects including group 1, healthy allogeneic donors given growth factors; group 2, patients with haematological malignancies mobilized with chemotherapy followed by growth factors; and group 3, patients with solid tumours mobilized with growth factors alone. A wide variation amongst subjects of the same category was observed. Group 1 and group 2 patients mobilized to a similar degree with a mean CD34(+) yield/kg of 3.44 x 10(6) and 3.39 x 10(6) respectively, for a standardized 2. 5 times blood volumes processed. This is superior to group 3 patients mobilized with growth factors alone who yielded only 0.99 x 10(6)/kg. A good correlation between peripheral blood CD34(+) count and leukapheresis yield was observed for all three groups. For healthy donors, prescheduled leukapheresis on day 5 after growth factors commencement predicts good yield, obviating the need for CD34 monitoring. On the contrary, most cancer patients mobilized with growth factors alone as in group 3 have inadequate single collection. They invariably require cumulative yield of several collections for adequate dose and hence predicting timing with peripheral blood CD34(+) count is not useful. In group 2 patients mobilized with chemotherapy followed by growth factors, we find that a peripheral blood CD34(+) count of 11/microL predicts collection of more than 1 x 10(6) CD34(+) cell/kg/2.5 blood volumes, thus helping to maximize yield and resources. J. Clin. Apheresis, 15:217-223, 2000. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11124688     DOI: 10.1002/1098-1101(2000)15:4<217::aid-jca1>3.0.co;2-z

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  4 in total

Review 1.  Stem cell transplantation for neuroblastoma.

Authors:  J D Fish; S A Grupp
Journal:  Bone Marrow Transplant       Date:  2007-11-26       Impact factor: 5.483

2.  Assessment of haematopoietic progenitor cell counting with the Sysmex® XN-1000 to guide timing of apheresis of peripheral blood stem cells.

Authors:  Francesco Dima; Erika Barison; Martina Midolo; Fabio Benedetti; Giuseppe Lippi
Journal:  Blood Transfus       Date:  2019-07-25       Impact factor: 3.443

3.  The new Sysmex XN-2000 automated blood cell analyzer more accurately measures the absolute number and the proportion of hematopoietic stem and progenitor cells than XE-2100 when compared to flow cytometric enumeration of CD34+ cells.

Authors:  Sang Hyuk Park; Chan-Jeoung Park; Mi-Jeong Kim; Min-Young Han; Sang-Hee Han; Young-Uk Cho; Seongsoo Jang
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

4.  Timing of peripheral blood stem cell yield: comparison of alternative methods with the classic method for CD34+ cell determination.

Authors:  I Fatorova; M Blaha; M Lanska; D Vokurkova; V Rezacova; P Zak
Journal:  Biomed Res Int       Date:  2014-09-08       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.